UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) June 8, 2011
 
Progenics Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
000-23143
 
13-3379479
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
         
777 Old Saw Mill River Road, Tarrytown, New York
 
10591
(Address of principal executive offices)
 
(Zip Code)
Registrant's telephone number, including area code (914) 789-2800
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 
 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e)         On June 8, 2011, Mark R. Baker, Chief Executive Officer of Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), was awarded 200,000 options under the Company’s 2005 Stock Incentive Plan in recognition of his appointment as CEO earlier this year.  The options vest in equal annual installments over four years and are exercisable at the closing price of the Company’s common stock on the date of grant.

Item 5.07. Submission of Matters to a Vote of Security Holders.

Progenics held its 2011 Annual Meeting of Stockholders on June 8, 2011. At the Meeting stockholders voted on (i) the election of directors; (ii) an advisory vote on the compensation of the Company’s named executive officers, (iii) an advisory stockholder indication of preferred frequency of executive compensation advisory votes, (iv) amendment of the Company’s charter to increase the number of authorized common shares from 40 million to 80 million, (v) amendment of the 2005 Stock Incentive Plan to increase the number of common shares available for issuance from 5,450,000 to 7,450,000, and (vi) ratification of the Board of Directors’ selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2011. The number of votes cast for and against or withheld, and abstentions and broker non-votes with respect to each matter are set forth below.
 
   
For
 
Against
 
Withheld
 
Broker Non-Votes
 1.  Election of Directors
             
 5,648,900
  Charles A. Baker
 
21,684,548
 
0
 
3,026,879
   
  Mark R. Baker
 
24,534,928
 
0
 
176,499
   
  Kurt W. Briner
 
24,571,938
 
0
 
139,489
   
  Peter J. Crowley
 
23,547,868
 
0
 
1,163,559
   
  Mark F. Dalton
 
23,539,350
 
0
 
1,172,077
   
  Stephen P. Goff, Ph.D.
 
21,183,027
 
0
 
3,528,400
   
  Paul J. Maddon, M.D., Ph.D.
 
24,459,714
 
0
 
251,713
   
  David A. Scheinberg, M.D., Ph.D.
 
24,536,736
 
0
 
174,691
   
  Nicole S. Williams
 
24,589,792
 
0
 
121,635
   
                 
   
For
 
Against
 
Abstain
 
Broker Non-Votes
2.  Advisory vote on compensation of named executive officers
 
23,442,422
 
1,262,442
 
6,563
 
5,648,900
                 
   
3 Years
 
2 Years
 
1 Year
 
Abstain
3.  Advisory indication of preferred frequency of executive compensation advisory votes
 
9,754,166
 
724,221
 
14,206,123
 
26,917
                 
   
For
 
Against
 
Abstain
 
Broker Non-Votes
4.  Charter amendment
 
27,728,560
 
2,618,111
 
13,656
 
0
                 
5.  Stock Incentive Plan amendment
 
22,775,269
 
1,935,008
 
1,150
 
5,648,900
                 
6.  Ratification of selection of PricewaterhouseCoopers LLP
 
30,314,121
 
43,333
 
2,873
 
0




 
 

 

SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
                         PROGENICS PHARMACEUTICALS, INC.
                         By:  /s/ ROBERT A. MCKINNEY                            
                            Robert A. McKinney
                            Chief Financial Officer, Senior Vice President,
                            Finance & Operations and Treasurer
 
 
 
Date:  June 13, 2011